Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

Tanguy Seiwert, MD
Published: Monday, May 01, 2017



Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The benefit with immunotherapy agents is a major positive step in the right direction for this field, Seiwert explains. However, it is also a first step as there is a lot of room for improvement and a hope to cure patients in the metastatic setting. There are reports, though, of patients surviving for a long time after achieving deep or complete responses.

The goal must be to continue this approach and move past minor partial responses, Seiwert says.


Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The benefit with immunotherapy agents is a major positive step in the right direction for this field, Seiwert explains. However, it is also a first step as there is a lot of room for improvement and a hope to cure patients in the metastatic setting. There are reports, though, of patients surviving for a long time after achieving deep or complete responses.

The goal must be to continue this approach and move past minor partial responses, Seiwert says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x